Know Cancer

forgot password

Serum, Plasma, DNA and Tissue Bank of Patients With Chronic Obstructive Pulmonary Disease, Lung Cancer and Smoking Controls.

25 Years
Open (Enrolling)
Chronic Obstructive Pulmonary Disease, Lung Cancer

Thank you

Trial Information

Serum, Plasma, DNA and Tissue Bank of Patients With Chronic Obstructive Pulmonary Disease, Lung Cancer and Smoking Controls.

All patients with a smoking history of at least 15 pack years, an minimal age of 50 years
and an recent available CT scan are enrolled.

All subjects with a diagnosis of lung cancer are also collected (irrespective of age and
smoking behavior).

In addition the investigators collect:

- specific questionnaires (MRC, CCQ and smoking history)

- medical and professional history

- complete pulmonary function (spirometry, bodyplethysmography and diffusing capacity)

- serum, plasma and DNA samples.

In specific subgroups the investigators also collect:

- Peripheral blood mononuclear cells

- Lung tissue - if available - from a surgical procedure (lung transplantation or

Inclusion Criteria

Inclusion Criteria for smokers:

- A smoking history of at least 15 pack years and age of 50 years or older

- Complete pulmonary function on day of visit

- Chest CT-scan within one year of enrollment

- 4 weeks from exacerbation

Exclusion Criteria for smokers:

- Less than 15 pack years

- Younger than 50 year

- Other pulmonary diseases interfering with CT or pulmonary function

- Asthma

Inclusion Criteria for lung cancer patients:

- new diagnosis of proven lung cancer

- chest CT scan within 2 months of enrollment

- Complete pulmonary function

Exclusion Criteria for lung cancer patients

- not able to perform pulmonary function

- Absence of histological diagnosis of lung cancer

Type of Study:


Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Serological, cytological, histological and genetic analysis of biomarkers or genes which are involved in the pathogenesis of COPD/Emphysema/Lungcancer.

Outcome Description:

All cases are prospectively collected in University hospital Leuven, Belgium. Of enrolled subjects data are collected at 0,1,3 and 6 years interval

Outcome Time Frame:

0-1-3-6 years

Safety Issue:


Principal Investigator

Wim Janssens, MD. PhD.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Katholieke Universiteit Leuven


Belgium: Institutional Review Board

Study ID:




Start Date:

October 2007

Completion Date:

Related Keywords:

  • Chronic Obstructive Pulmonary Disease
  • Lung Cancer
  • COPD
  • Lung cancer
  • genes
  • DNA
  • Lung Diseases
  • Respiration Disorders
  • Pulmonary Disease, Chronic Obstructive
  • Lung Neoplasms
  • Lung Diseases, Obstructive